X

Quality Statement

Pacific Biosciences is committed to providing high-quality products that meet customer expectations and comply with regulations. We will achieve these goals by adhering to and maintaining an effective quality-management system designed to ensure product quality, performance, and safety.

X

Image Use Agreement

By downloading, copying, or making any use of the images located on this website (“Site”) you acknowledge that you have read and understand, and agree to, the terms of this Image Usage Agreement, as well as the terms provided on the Legal Notices webpage, which together govern your use of the images as provided below. If you do not agree to such terms, do not download, copy or use the images in any way, unless you have written permission signed by an authorized Pacific Biosciences representative.

Subject to the terms of this Agreement and the terms provided on the Legal Notices webpage (to the extent they do not conflict with the terms of this Agreement), you may use the images on the Site solely for (a) editorial use by press and/or industry analysts, (b) in connection with a normal, peer-reviewed, scientific publication, book or presentation, or the like. You may not alter or modify any image, in whole or in part, for any reason. You may not use any image in a manner that misrepresents the associated Pacific Biosciences product, service or technology or any associated characteristics, data, or properties thereof. You also may not use any image in a manner that denotes some representation or warranty (express, implied or statutory) from Pacific Biosciences of the product, service or technology. The rights granted by this Agreement are personal to you and are not transferable by you to another party.

You, and not Pacific Biosciences, are responsible for your use of the images. You acknowledge and agree that any misuse of the images or breach of this Agreement will cause Pacific Biosciences irreparable harm. Pacific Biosciences is either an owner or licensee of the image, and not an agent for the owner. You agree to give Pacific Biosciences a credit line as follows: "Courtesy of Pacific Biosciences of California, Inc., Menlo Park, CA, USA" and also include any other credits or acknowledgments noted by Pacific Biosciences. You must include any copyright notice originally included with the images on all copies.

IMAGES ARE PROVIDED BY Pacific Biosciences ON AN "AS-IS" BASIS. Pacific Biosciences DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS, IMPLIED OR STATUTORY, INCLUDING, BUT NOT LIMITED TO, NON-INFRINGEMENT, OWNERSHIP, MERCHANTABILITY AND FITNESS FOR A PARTICULAR PURPOSE. IN NO EVENT SHALL Pacific Biosciences BE LIABLE FOR ANY DIRECT, INDIRECT, INCIDENTAL, PUNITIVE, OR CONSEQUENTIAL DAMAGES OF ANY KIND WHATSOEVER WITH RESPECT TO THE IMAGES.

You agree that Pacific Biosciences may terminate your access to and use of the images located on the PacificBiosciences.com website at any time and without prior notice, if it considers you to have violated any of the terms of this Image Use Agreement. You agree to indemnify, defend and hold harmless Pacific Biosciences, its officers, directors, employees, agents, licensors, suppliers and any third party information providers to the Site from and against all losses, expenses, damages and costs, including reasonable attorneys' fees, resulting from any violation by you of the terms of this Image Use Agreement or Pacific Biosciences' termination of your access to or use of the Site. Termination will not affect Pacific Biosciences' rights or your obligations which accrued before the termination.

I have read and understand, and agree to, the Image Usage Agreement.

I disagree and would like to return to the Pacific Biosciences home page.

Pacific Biosciences
Contact:

Management team

 

Christian Henry | CEO & President

Christian Henry | CEO & President

Christian Henry has more than two decades of experience with growing companies in the life sciences industry. From 2005 through January 2017, Mr. Henry was an executive at Illumina, Inc., where he served in a number of different roles including Chief Financial Officer, Chief Commercial Officer and General Manager of the Life Sciences Business. Prior to Illumina, Mr. Henry was Chief Financial Officer for Tickets.com, a publicly traded online ticket provider, which was acquired by Major League Baseball Advanced Media, LP. Mr. Henry also served as Vice President of Finance and Corporate Controller for Affymetrix, Inc., and held a similar position at Nektar Therapeutics (formerly Inhale Therapeutic Systems, Inc.). Mr. Henry earned a B.A. in biochemistry and cell biology from the University of California, San Diego and an MBA from the University of California, Irvine.


Brett Atkins, Ph.D. | General Counsel

Brett Atkins, J.D., Ph.D. | General Counsel

Brett Atkins is the General Counsel of Pacific Biosciences and has more than fifteen years of corporate legal experience with companies in the life sciences industry. Dr. Atkins is responsible for all legal matters at Pacific Biosciences and he advises on every aspect of the company’s business, including corporate securities and governance, SEC reporting, mergers and acquisitions, IP transactions, commercial sales and operations, manufacturing and supply arrangements, executive and employee compensation, human resources, compliance and facilities issues. Prior to Pacific Biosciences, Dr. Atkins served as a senior level corporate attorney at leading publicly traded biotech and pharma companies and, before that, at large international law firms with a focus on the life sciences industry. Dr. Atkins earned a J.D. from the University of San Diego School of Law, a Ph.D. in Biochemistry from the University of Arkansas for Medical Sciences and a B.A. in Chemistry from Austin College.


Peter Fromen | Chief Commercial Officer

Peter Fromen | Chief Commercial Officer

Peter Fromen brings over twenty years of experience from the life sciences and genomics industries, building and leading teams in numerous areas of responsibility. Peter joined Pacific Biosciences after 14 years at Illumina, where most recently he served as Global Vice President of Population Genomics and Precision Health and was responsible for product management, market development, and market strategy across Genetic Disease Research and Testing, Population Genomics, Health Systems and Consumer Genomics. Peter joined Illumina in 2007 to build and lead the firm’s first investor relations function before he transitioned to the commercial organization, leading product marketing activities across multiple business units, and had a leading role in launching several of the company’s high-throughput sequencers. In 2015, with population genomics starting to emerge, Peter relocated to London to oversee Illumina’s partnership with Genomics England and the National Health Service (NHS) to execute the 100,000 Genomes Project and subsequently embed clinical whole genome sequencing as standard of care in the NHS Genomic Medicine Service for rare disease and cancer patients. In this role, Peter and his team were responsible for expanding the company’s global Population Genomics business to enable precision medicine at a population level from market development to enterprise sales.

Prior to joining Illumina, Peter held leadership positions at Applied Biosystems and Agilent Technologies in corporate finance and investor relations roles. He first entered the life sciences industry on the investment side while at Howard Capital Management in New York as an equity research analyst and portfolio manager covering life sciences and technology companies. Peter holds a bachelor’s degree in History with a concentration in Environmental Science from Kenyon College, and an MBA from the W. P. Carey School of Business at Arizona State University.


Mike Goloubef | Vice President, Manufacturing and Quality

Mike Goloubef | Vice President, Manufacturing and Quality

Mike Goloubef is a seasoned hands-on global operations and quality leader with more than three decades of experience with high growth companies. He has worked in several industries including Life Sciences, Biotech, Detection/Sensor Technologies and Electronic Consumer, Industrial and Military goods. Mike joined Pacific Biosciences in 2020 after holding senior operations and quality roles in Thermo Fisher Scientific from 2010 – 2019 and MDS & AB SCIEX/Danaher from 1995 – 2010. Mike held several key roles including Vice President Operations & Quality, Vice President Global Manufacturing and Managing Director. While at Thermo Fisher, Mike ran the operations and quality groups for the Chemical Analysis division with revenues in excess of $1B and the Chromatography & Mass Spectrometry division with revenue in excess of $2B. While at MDS & AB SCIEX/Danaher, he ran the global manufacturing and quality groups and as an expat, led a green field start-up in Singapore where he was instrumental in shifting their Mass Spec production.

Mike has broad global operations, supply chain, logistics and quality experience and has used those skills to support both the tactical needs of delivering consistent quarter over quarter results as well as developing longer term strategic plans. He has supported several M & A activities and was a senior integration leader during the acquisition of Molecular Devices by MDS SCIEX and later MDS SCIEX by the Danaher Corporation. Mike has also been active in supporting a number of critical corporate projects, most recently at Thermo Fisher where he successfully led the companies Brexit and China Tariff initiatives.

He has earned a Bachelor of Technology Degree in Industrial Engineering from Ryerson University in Toronto, Ontario, Canada and an MBA from the University of Surrey (IMC) in Surrey, England.


Susan Kim | Chief Financial Officer

Susan Kim | Chief Financial Officer

Susan Kim brings twenty years of senior level finance and operations experience to Pacific Biosciences. Ms. Kim most recently served as Chief Financial Officer for App Annie and Katerra, both leading venture-backed technology companies. In these roles, she was instrumental in driving revenue growth, scaling finance and operations, and realizing synergies through strategic acquisitions. From 2010 to 2016, Ms. Kim held various leadership roles at KLA Corporation (NASDAQ: KLAC). Prior to KLA, she was an investment banker in Morgan Stanley’s technology practice and started her career as a semiconductor manufacturing engineer for Advanced Micro Devices (NASDAQ: AMD). Ms. Kim earned a B.S. in Chemical Engineering from Stanford University and an MBA and Master of Engineering Management from Kellogg School of Management, Northwestern University. In 2019, Ms. Kim was recognized as one of the Most Influential Women in Bay Area Business by the San Francisco Business Times.


Jonas Korlach, Ph.D. | Chief Scientific Officer

Jonas Korlach, Ph.D. | Chief Scientific Officer

Jonas Korlach was appointed Chief Scientific Officer of Pacific Biosciences in July 2012. He was previously a Scientific Fellow, supporting commercial development of the PacBio RS II system and performing research aimed at developing new applications for SMRT technologies. He co-invented the SMRT technology with Stephen Turner, Ph.D., Pacific Biosciences Founder and Chief Technology Officer, when the two were graduate students at Cornell University. Dr. Korlach joined Pacific Biosciences as the company’s eighth employee in 2004. Previously, he was a Postdoctoral Researcher at Cornell University.

Dr. Korlach is the recipient of multiple grants, an inventor on 70 issued U.S. patents and 61 international patents, and an author of over 70 scientific studies on the principles and applications of SMRT technology, including publications in Nature, Science, and PNAS. In 2013, Dr. Korlach was honored by the Obama White House as an Immigrant Innovator “Champion of Change.” He received both his Ph.D. and his M.S. degrees in Biochemistry, Molecular and Cell Biology from Cornell, and received M.S. and B.A. degrees in Biological Sciences from Humboldt University in Berlin, Germany.


Kathleen Lynch | Head of Global Government Affairs and Corporate Communications

Kathleen Lynch | Head of Global Government Affairs and Corporate Communications

Kathy Lynch is an experienced and driven healthcare advocate who brings over 20 years of government and external affairs experience to Pacific Biosciences. She joins the company from Illumina Inc., where she served as the Vice President, Global Government Affairs & Public Policy. Kathy joined Illumina in 2015 to launch the company’s government affairs function and was responsible for the development and implementation of Illumina’s global government affairs strategy. While in this role, she managed complex policy issues in front of the U.S government, state governments, and over 20 key markets across the globe. Prior to her tenure at Illumina, Kathy served as the Senior Director of Government Relations at Thermo Fisher Scientific and Life Technologies. At Life Technologies, she also served as Chief of Staff to the President and Chief Operating Officer. Before transitioning to government and external affairs, Kathy worked as a corporate attorney practicing in New York and Massachusetts. In 2020, Kathy was recognized as one of the top 500 influential community leaders in San Diego by the San Diego Business Journal.

Kathy is on the board of the Rady Children’s Institute for Genomic Medicine. She earned a Bachelor of Arts degree from the University of New Hampshire and a Juris Doctorate from St. John’s University School of Law.


Stephen Turner, Ph.D. | Chief Technical Officer

Stephen Turner, Ph.D. | Chief Technical Officer

Dr. Turner founded Pacific Biosciences (formerly Nanofluidics) and in 2004 secured its Series A funding. He was awarded a Ph.D. in Physics by Cornell University in 2000, where he worked with Prof. Harold Craighead to study the behavior of biomolecules in nano-fabricated structures. He was a member of the project team at Cornell which developed the technology now employed by Pacific Biosciences and was co-author of the cover story in Science magazine (January 31, 2003) that introduced the technology to the scientific community. Dr. Turner’s undergraduate work was at the University of Wisconsin, Madison, where he received a Bachelor of Science in Applied Mathematics, Electrical Engineering and Physics. He is the author of over 50 scientific papers in fields ranging from DNA sequencing technology and biophysics to genomics and epigenomics. He is listed as the inventor on over 50 U.S. patents and numerous published patent applications. Dr. Turner was recipient of the MIT Technology Review “TR100” Award in 2003 and the University of Wisconsin Madison Distinguished Young Alumnus Award in 2008


Mark Van Oene | Chief Operating Officer

Mark Van Oene | Chief Operating Officer

Mark recently joined Pacific Biosciences in the newly created role of Chief Operating Officer where he will manage our research, development and manufacturing organizations and will be responsible for driving our strategic planning and corporate development activities

Mark joins the company from Illumina, Inc. where he most recently served as Senior Vice President and Chief Commercial Officer. In that role, he was responsible for the development and implementation of lllumina’s commercial strategy and oversaw worldwide sales and services of over $3B in annual revenue and ~1,800 commercial employees.

He joined Illumina in 2006 as a regional account manager in Illumina’s sales organization, and advanced rapidly taking on senior commercial leadership roles with ever increasing areas of responsibility, ultimately assuming the Chief Commercial Officer role in 2017. During his fifteen year tenure at Illumina, he was instrumental in scaling Illumina’s global commercial organization, representing the voice of their customers and driving significant annual revenue growth.

Prior to Illumina, Mark was the Director of Genotyping Services for Ellipsis Biotherapeutics.

He earned as B.S. in Biochemistry from Western University and was a Ph.D. candidate at the University of Toronto in the department of Molecular and Medical Genetics. During that time, his research was focused on Cystic Fibrosis at the Hospital for Sick Children in Toronto.


Natalie Welch - Chief People Officer

Natalie Welch | Chief People Officer

Natalie Welch serves as Chief People Officer for Pacific Biosciences. In her current role, Ms. Welch is responsible for leading PacBio’s overall human resources strategy, global talent management, organizational design, culture and community development. Natalie is a people-focused, results-driven executive with more than 20 years of experience in diverse industries and geographies. Natalie joined Pacific Biosciences in 2008 after a 15-year tenure with a hospitality company where she was responsible for people relations, talent planning, and learning and development initiatives. During the last 12 years, she served in various roles of increasing responsibility in Human Resources and Organizational Development for PacBio, building strong relationships to become a trusted partner with leadership, board teams and employees across the company. Now as Chief of People, Natalie is changing the function, culture, and impact of HR across the Company to support its business goals and strategy, as well as the changing dynamics for employees working across the globe. Natalie holds a B.S. degree in Psychology and post-graduate work in Counseling Psychology from The College of New Jersey.


Denis Zaccarin, Ph.D. | Senior Vice President, Research and Development

Denis Zaccarin, Ph.D. | Senior Vice President, Research and Development

Denis joined Pacific Biosciences in 2004 as Director of Engineering. He initially led the development of the research tools used by Pacific Biosciences to generate the first sequencing results. He was promoted to Vice President of Engineering in 2010 and managed the development of the first commercial platform, RSII. Since 2012 he has been occupying the role of VP Semiconductor Integration Devices, leading the development of the consumables used in the Sequel and Sequel II platforms. Prior to joining Pacific Biosciences, Dr. Zaccarin held various engineering and leadership roles at Bell-Northern Research, Nortel, Cambrian Systems, ONI systems and Ciena. Dr. Zaccarin was promoted to Senior Vice President, Research and Development, effective April 1, 2020. Dr. Zaccarin holds B.Sc.E (1987) and M.Sc.E (1989) from Laval University and a Ph.D in Electrical Engineering, Optics (1993) from the University of Ottawa.